This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TOCA vs. CALT, ZYME, CMRX, CDMO, MENS, SBTX, MBX, RVNC, CKPT, and AVTEShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), and Aerovate Therapeutics (AVTE). Tocagen vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Chimerix Avid Bioservices Jyong Biotech Silverback Therapeutics MBX Biosciences Revance Therapeutics Checkpoint Therapeutics Aerovate Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Which has better valuation and earnings, CALT or TOCA? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Tocagen. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Tocagen$40K8,168.34-$63.52M-$2.69-5.08 Is CALT or TOCA more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Tocagen's net margin of -176,433.34%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Tocagen -176,433.34%-327.74%-111.87% Which has more volatility & risk, CALT or TOCA? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Do institutionals & insiders believe in CALT or TOCA? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 21.4% of Tocagen shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 10.9% of Tocagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to CALT or TOCA? In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Tocagen'saverage media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Tocagen Neutral SummaryCalliditas Therapeutics AB (publ) beats Tocagen on 7 of the 11 factors compared between the two stocks. Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$326.73M$790.73M$5.53B$9.05BDividend YieldN/A4.84%5.24%4.03%P/E Ratio-5.761.1327.5020.21Price / Sales8,168.34226.97421.02118.64Price / CashN/A23.4436.8958.07Price / Book30.366.298.045.67Net Income-$63.52M-$27.73M$3.18B$249.13M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$13.66-1.3%N/A+2,541.7%$326.73M$40K-5.7677CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.0101 of 5 stars$12.41-1.1%$21.00+69.2%+53.0%$863.45M$93.38M-8.27460Analyst ForecastCMRXChimerix0.7552 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.7254 of 5 stars$12.50+0.1%$12.25-2.0%+62.3%$799.18M$139.91M-5.23320High Trading VolumeMENSJyong BiotechN/A$8.48-0.2%N/AN/A$646.23MN/A0.0031SBTXSilverback TherapeuticsN/A$17.45-4.1%N/A+84.3%$629.21MN/A-7.2183High Trading VolumeMBXMBX Biosciences2.4186 of 5 stars$11.61+1.8%$37.50+223.0%N/A$388.05MN/A0.0036RVNCRevance Therapeutics2.7987 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.5057 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210AVTEAerovate TherapeuticsN/A$9.99+8.7%N/A-81.7%$289.56MN/A-3.3420High Trading Volume Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Chimerix Alternatives Avid Bioservices Alternatives Jyong Biotech Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Revance Therapeutics Alternatives Checkpoint Therapeutics Alternatives Aerovate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TOCA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
